Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRise 4: TAR-200 + cetrelimab vs cetrelimab in muscle-invasive urothelial carcinoma of the bladder
2023-507189-17-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) comparing TAR-200 + cetrelimab with Cetrelimab alone (2 arms). Primary endpoint: Pathologic complete response (pCR) rate at radical cystectomy. Started May 2024; status: completed.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2023-507189-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507189-17-00.